#junshi-biosciences

Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026

Junshi Biosciences announced positive Phase 3 NEOTORCH trial results for its cancer drug toripalimab at the ESMO Congress 2026. The therapy demonstrated significant improvements in event-free and overall survival for lung cancer patients.